RNS Announcements

2023

ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces that Mikkel Hvid-Hansen, Commercial Director and Board member of the Company, has resigned from his position to pursue other opportunities, effective from 28 February 2024.

Separately, the Company announces the appointment of Michael Litichevski as Head of Global Sales as of 1 January 2024. The appointment of Michael is part of the Company’s strategy to build a strong commercial team to support the long-term growth of ProBiotix. Michael joins ProBiotix from Lactobio, a microbial solutions and microbiome skincare company with a live bacteria business. He has over 25 years’ experience in building B2B segments with more than 11 years of this specifically within the probiotics dietary supplements industry. He was previously VP of Sales at Deerland Probiotics & Enzymes, VP sales of Bifodan and has worked for large organisations such as Orkla brands and Nycomed. Michael has extensive experience with the commercialisation of innovative and high-quality probiotic solutions which is in line with the Company's strategical direction of finished supplement dosage format. He has good connections in the industry and has the ability to create strong and valuable partnerships.

Steen Andersen, CEO of ProBiotix Health plc commented: “We are sad to see Mikkel leave us but wish him well in his future endeavours. He has held the role of European Sales Director and Commercial Director at ProBiotix for the last four years, since before we listed on Aquis, and has brought a wealth of knowledge and expertise to the role. The Board would like to thank him for his service and guidance.

“We would also like to extend a warm welcome  to Michael as our new Head of Global Sales. I am confident that he will be a huge asset to the commercial team and will greatly contribute to building our B2B business both locally and globally. He brings vast experience in sales leadership combined with scientific knowledge from global leading probiotic companies to support ProBiotix's strategy and sales on an international level.”

For further information, please contact:

Market Abuse Regulation (MAR) Disclosure

2022

ProBiotix Health plc (AQUIS: PBX), a life sciences business developing probiotics to support cardiometabolic health, announces that Mikkel Hvid-Hansen, Commercial Director and Board member of the Company, has resigned from his position to pursue other opportunities, effective from 28 February 2024.

Separately, the Company announces the appointment of Michael Litichevski as Head of Global Sales as of 1 January 2024. The appointment of Michael is part of the Company’s strategy to build a strong commercial team to support the long-term growth of ProBiotix. Michael joins ProBiotix from Lactobio, a microbial solutions and microbiome skincare company with a live bacteria business. He has over 25 years’ experience in building B2B segments with more than 11 years of this specifically within the probiotics dietary supplements industry. He was previously VP of Sales at Deerland Probiotics & Enzymes, VP sales of Bifodan and has worked for large organisations such as Orkla brands and Nycomed. Michael has extensive experience with the commercialisation of innovative and high-quality probiotic solutions which is in line with the Company's strategical direction of finished supplement dosage format. He has good connections in the industry and has the ability to create strong and valuable partnerships.

Steen Andersen, CEO of ProBiotix Health plc commented: “We are sad to see Mikkel leave us but wish him well in his future endeavours. He has held the role of European Sales Director and Commercial Director at ProBiotix for the last four years, since before we listed on Aquis, and has brought a wealth of knowledge and expertise to the role. The Board would like to thank him for his service and guidance.

“We would also like to extend a warm welcome  to Michael as our new Head of Global Sales. I am confident that he will be a huge asset to the commercial team and will greatly contribute to building our B2B business both locally and globally. He brings vast experience in sales leadership combined with scientific knowledge from global leading probiotic companies to support ProBiotix's strategy and sales on an international level.”

For further information, please contact:

Market Abuse Regulation (MAR) Disclosure